Trials / Completed
CompletedNCT04719832
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 395 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an eosinophilic phenotype
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK3511294 (Depemokimab) | GSK3511294 (Depemokimab) will be administered using a pre-filled syringe. |
| DRUG | Placebo | Matching placebo will be administered as a normal saline using a pre-filled syringe. |
Timeline
- Start date
- 2021-03-17
- Primary completion
- 2023-11-21
- Completion
- 2023-11-21
- First posted
- 2021-01-22
- Last updated
- 2024-12-17
- Results posted
- 2024-12-17
Locations
123 sites across 12 countries: United States, Canada, China, Czechia, France, Germany, Ireland, Italy, Poland, Russia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04719832. Inclusion in this directory is not an endorsement.